Skip to main content
Premium Trial:

Request an Annual Quote

Enzymatics Buys ArcherDx for up to $50M

NEW YORK (GenomeWeb News) – Enzymatics today announced it has bought ArcherDx, a developer of kits and software solutions for next-generation sequencing, for up to $50 million.

The deal, consisting of cash, equity, and potential milestones, provides Beverly, Mass.-based Enzymatics with genomics capabilities that complement its Enzymatics Supply Chain Solutions and Enzymatics Reagents groups, it said. The acquisition, the company added, also expands the new Enzymatics Diagnostics groups with technology, kits, and analytical solutions for hospitals, research institutions, and other diagnostic providers for the rapid and cost-effective assessment of genetic biomarkers.

In conjunction with the transaction, ArcherDx Co-founder and CEO Jason Myers is joining Enzymatics as chief scientific officer. ArcherDx is based in Boulder, Colo.

"An unprecedented growth in genomics for healthcare is fueling greater demand for faster, more accurate, and more cost effective sequencing applications," Enzymatics' President and CEO Jon DiVincenzo said in a statement. "We are seeing double-digit growth in the placement of new sequencers every year and broad adoption of genomic technologies across clinical communities. Enzymatics, which already supplies reagents and kits to approximately 80 percent of the NGS industry, together with ArcherDx, will bring novel sequencing applications more directly to clinical researchers."